Studying CENP-V Protein Levels to Detect Damage in Human Oocytes from Women Aged 18 to 45 Comparing Oocytes from Women with Advanced Maternal Age and Younger Controls Including Analysis Before and After Oocyte Freezing and Thawing Procedures

What this Trial Is About

Researchers are investigating the levels of the CENP-V protein in human oocytes to understand its role as a potential diagnostic marker for oocyte damage related to aging and the freezing process called vitrification. The study focuses on women with advanced maternal age AMA and compares them to younger control patients. The research addresses a concern that aging and freezing may reduce oocyte quality, affecting fertility and survival rates after thawing. The study involves analyzing immature oocytes that would otherwise be discarded from patients with AMA and control patients, as well as oocytes subjected to vitrification and thawing. Patients are divided into groups by age and fertility status, including those undergoing ovarian stimulation and oocyte collection. Only immature or donated mature oocytes not used for treatment are included in the analysis. Participants will have their oocytes collected and assessed within two days from enrollment to retrieval. The study measures the levels and distribution of CENP-V in these oocytes and tracks the survival rate of oocyte cohorts after thawing. This observational study does not involve treatment but focuses on laboratory analysis to identify markers of oocyte damage, which could inform future fertility evaluations.

CENP-V As a Potential Diagnostic Marker of Damage in Human Oocytes